PRNewsWire
04 Aug 2026, 00:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ADMA Biologics is facing a class action lawsuit alleging the company used channel stuffing to inflate revenues and engaged in undisclosed related party transactions. — Allegations of financial fraud, specifically revenue manipulation and internal control failures, are severe catalysts for stock price devaluation.
-0.80Culper Research report claims ADMA's reported 20% growth was actually a 3% decline when adjusted for payment term extensions. — A significant discrepancy between reported and 'real' growth suggests fundamental business deterioration and a misleading valuation.
-0.70Cantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral following concerns over the short-seller report. — A downgrade from a major institutional analyst indicates a loss of professional confidence in the company's outlook.
-0.50Continue reading
6 related stories
Top 1 mover · tap to explore
The law firm Robbins Geller Rudman & Dowd LLP has set an August 10, 2026 deadline for investors to seek appointment as lead plaintiff in the lawsuit. — While primarily a procedural legal step, the formalization of a class action increases the likelihood of future financial settlements/liabilities.
-0.20Which stocks this story touches
The company is facing a class action lawsuit alleging securities fraud, channel stuffing, and misleading statements, following a significant stock price decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
40m ago
